18/03/2022 — Laevoroc Oncology Announces Evolution of Former Subsidiary into Joint Venture with Lipomed AG
Laevoroc Chemotherapy will develop a new oral gemcitabine prodrug, LR 06B, aiming to make a positive impact on health equity and quality of care for cancer patients around the world...